贝瑞基因
(000710)
| 流通市值：47.27亿 | | | 总市值：51.12亿 |
| 流通股本：3.27亿 | | | 总股本：3.54亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 217,759,068.08 | 1,078,165,273.94 | 822,664,528.62 | 551,776,302.07 |
| 营业收入 | 217,759,068.08 | 1,078,165,273.94 | 822,664,528.62 | 551,776,302.07 |
| 二、营业总成本 | 214,518,555.65 | 1,072,541,450.25 | 765,979,082.06 | 508,721,669.59 |
| 营业成本 | 110,008,040.12 | 572,909,344.39 | 406,324,355.34 | 263,774,077.25 |
| 税金及附加 | 414,696.25 | 11,236,018.57 | 6,391,977.92 | 5,027,568.68 |
| 销售费用 | 47,819,719.97 | 236,830,171.84 | 171,214,504.94 | 118,094,609.35 |
| 管理费用 | 33,141,322.58 | 148,723,794.38 | 119,317,330.32 | 77,472,664.04 |
| 研发费用 | 21,653,803.47 | 95,419,662.22 | 58,453,739.7 | 39,768,904.04 |
| 财务费用 | 1,480,973.26 | 7,422,458.85 | 4,277,173.84 | 4,583,846.23 |
| 其中:利息费用 | 2,209,183.91 | 9,831,402.96 | - | 6,392,136.14 |
| 其中:利息收入 | -900,869.89 | 3,522,477.58 | - | 1,845,526.9 |
| 加:公允价值变动收益 | -2,276,101.9 | -132,165.22 | -2,230,529.83 | -70,132.47 |
| 加:投资收益 | 954,578.63 | -14,553,527.69 | -6,798,926.38 | -5,041,657.7 |
| 资产处置收益 | -14,866.73 | 1,739,687.32 | 4,598,331.96 | 29,106.52 |
| 资产减值损失(新) | - | -28,078,288.63 | - | - |
| 信用减值损失(新) | -5,459,820.52 | -132,930,004.56 | -26,450,355.96 | -17,453,976.35 |
| 其他收益 | 425,716.91 | 1,717,510.77 | 1,542,459.11 | 1,170,329.93 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -3,129,981.18 | -166,612,964.32 | 27,346,425.46 | 21,688,302.41 |
| 加:营业外收入 | 2,922.26 | 258,807.15 | 234,871.58 | 224,873.34 |
| 减:营业外支出 | 618,144.78 | 4,403,254.13 | 1,284,017.73 | 1,095,412.59 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -3,745,203.7 | -170,757,411.3 | 26,297,279.31 | 20,817,763.16 |
| 减:所得税费用 | 1,894,516.73 | 17,417,622.98 | 12,352,762.31 | 8,748,419.34 |
| 六、净利润 | -5,639,720.43 | -188,175,034.28 | 13,944,517 | 12,069,343.82 |
| 持续经营净利润 | -5,639,720.43 | -188,175,034.28 | 13,944,517 | 12,069,343.82 |
| 归属于母公司股东的净利润 | -6,462,206.12 | -192,428,499.73 | 10,385,508.92 | 9,262,843.84 |
| 少数股东损益 | 822,485.69 | 4,253,465.45 | 3,559,008.08 | 2,806,499.98 |
| (一)基本每股收益 | -0.02 | -0.54 | 0.03 | 0.03 |
| (二)稀释每股收益 | -0.02 | -0.54 | 0.03 | 0.03 |
| 八、其他综合收益 | -814,304.19 | 5,461,696.08 | -480,248.25 | 908,278.13 |
| 归属于母公司股东的其他综合收益 | -669,245.91 | 4,595,883.99 | -332,858.02 | 573,313.98 |
| 九、综合收益总额 | -6,454,024.62 | -182,713,338.2 | 13,464,268.75 | 12,977,621.95 |
| 归属于母公司股东的综合收益总额 | -7,131,452.03 | -187,832,615.74 | 10,052,650.9 | 9,836,157.82 |
| 归属于少数股东的综合收益总额 | 677,427.41 | 5,119,277.54 | 3,411,617.85 | 3,141,464.13 |
| 公告日期 | 2025-04-28 | 2025-04-25 | 2024-10-29 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |